Table of Content

1 Report Overview
1.1 Relapsed Acute Myeloid Leukemia Drug Definition
1.2 Market by Type
1.2.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 aNK Program
1.2.3 AT-9283
1.2.4 BI-836858
1.2.5 Binimetinib
1.2.6 BL-8040
1.2.7 Others
1.3 Market Segment by Application
1.3.1 Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Relapsed Acute Myeloid Leukemia Drug Sales
2.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region
2.3.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2018-2023)
2.3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2024-2034)
2.4 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region
2.6.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Manufacturers
3.1.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Relapsed Acute Myeloid Leukemia Drug Sales in 2024
3.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers
3.2.1 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Relapsed Acute Myeloid Leukemia Drug Revenue in 2024
3.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Price by Manufacturers
3.4 Global Key Players of Relapsed Acute Myeloid Leukemia Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Product Offered and Application
3.8 Global Key Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type
4.1.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type
4.2.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2018-2034)
4.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Type
4.3.1 Global Relapsed Acute Myeloid Leukemia Drug Price by Type (2018-2023)
4.3.2 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application
5.1.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application
5.2.1 Global Relapsed Acute Myeloid Leukemia Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Relapsed Acute Myeloid Leukemia Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2018-2034)
5.3 Global Relapsed Acute Myeloid Leukemia Drug Price by Application
5.3.1 Global Relapsed Acute Myeloid Leukemia Drug Price by Application (2018-2023)
5.3.2 Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Relapsed Acute Myeloid Leukemia Drug Sales by Company
6.1.1 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023)
6.1.2 North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023)
6.2 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
6.2.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2034)
6.3 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
6.3.1 North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2034)
6.4 North America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
6.4.1 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2018-2034)
6.4.3 North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales by Company
7.1.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023)
7.2 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Type
7.2.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2034)
7.3 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Application
7.3.1 Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2034)
7.4 Europe Relapsed Acute Myeloid Leukemia Drug Market Size by Country
7.4.1 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2018-2034)
7.4.3 Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Relapsed Acute Myeloid Leukemia Drug Sales by Company
8.1.1 China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023)
8.1.2 China Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023)
8.2 China Relapsed Acute Myeloid Leukemia Drug Market Size by Type
8.2.1 China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2034)
8.2.2 China Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2034)
8.3 China Relapsed Acute Myeloid Leukemia Drug Market Size by Application
8.3.1 China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2034)
8.3.2 China Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Relapsed Acute Myeloid Leukemia Drug Sales by Company
9.1.1 APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023)
9.2 APAC Relapsed Acute Myeloid Leukemia Drug Market Size by Type
9.2.1 APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2034)
9.3 APAC Relapsed Acute Myeloid Leukemia Drug Market Size by Application
9.3.1 APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2034)
9.4 APAC Relapsed Acute Myeloid Leukemia Drug Market Size by Region
9.4.1 APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2018-2034)
9.4.3 APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 4SC AG
11.1.1 4SC AG Company Information
11.1.2 4SC AG Overview
11.1.3 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 4SC AG Relapsed Acute Myeloid Leukemia Drug Products and Services
11.1.5 4SC AG Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.1.6 4SC AG Recent Developments
11.2 AbbVie Inc.
11.2.1 AbbVie Inc. Company Information
11.2.2 AbbVie Inc. Overview
11.2.3 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.2.5 AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.2.6 AbbVie Inc. Recent Developments
11.3 Actinium Pharmaceuticals, Inc.
11.3.1 Actinium Pharmaceuticals, Inc. Company Information
11.3.2 Actinium Pharmaceuticals, Inc. Overview
11.3.3 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.3.5 Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.3.6 Actinium Pharmaceuticals, Inc. Recent Developments
11.4 Agios Pharmaceuticals, Inc.
11.4.1 Agios Pharmaceuticals, Inc. Company Information
11.4.2 Agios Pharmaceuticals, Inc. Overview
11.4.3 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.4.5 Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.4.6 Agios Pharmaceuticals, Inc. Recent Developments
11.5 Amgen Inc.
11.5.1 Amgen Inc. Company Information
11.5.2 Amgen Inc. Overview
11.5.3 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.5.5 Amgen Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.5.6 Amgen Inc. Recent Developments
11.6 Arog Pharmaceuticals, Inc.
11.6.1 Arog Pharmaceuticals, Inc. Company Information
11.6.2 Arog Pharmaceuticals, Inc. Overview
11.6.3 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.6.5 Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.6.6 Arog Pharmaceuticals, Inc. Recent Developments
11.7 Array BioPharma Inc.
11.7.1 Array BioPharma Inc. Company Information
11.7.2 Array BioPharma Inc. Overview
11.7.3 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.7.5 Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.7.6 Array BioPharma Inc. Recent Developments
11.8 Astellas Pharma Inc.
11.8.1 Astellas Pharma Inc. Company Information
11.8.2 Astellas Pharma Inc. Overview
11.8.3 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.8.5 Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.8.6 Astellas Pharma Inc. Recent Developments
11.9 Astex Pharmaceuticals, Inc.
11.9.1 Astex Pharmaceuticals, Inc. Company Information
11.9.2 Astex Pharmaceuticals, Inc. Overview
11.9.3 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.9.5 Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.9.6 Astex Pharmaceuticals, Inc. Recent Developments
11.10 AstraZeneca Plc
11.10.1 AstraZeneca Plc Company Information
11.10.2 AstraZeneca Plc Overview
11.10.3 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Products and Services
11.10.5 AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
11.10.6 AstraZeneca Plc Recent Developments
11.11 AVEO Pharmaceuticals, Inc.
11.11.1 AVEO Pharmaceuticals, Inc. Company Information
11.11.2 AVEO Pharmaceuticals, Inc. Overview
11.11.3 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.11.5 AVEO Pharmaceuticals, Inc. Recent Developments
11.12 BioLineRx, Ltd.
11.12.1 BioLineRx, Ltd. Company Information
11.12.2 BioLineRx, Ltd. Overview
11.12.3 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.12.5 BioLineRx, Ltd. Recent Developments
11.13 Boehringer Ingelheim GmbH
11.13.1 Boehringer Ingelheim GmbH Company Information
11.13.2 Boehringer Ingelheim GmbH Overview
11.13.3 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Products and Services
11.13.5 Boehringer Ingelheim GmbH Recent Developments
11.14 Boston Biomedical, Inc.
11.14.1 Boston Biomedical, Inc. Company Information
11.14.2 Boston Biomedical, Inc. Overview
11.14.3 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.14.5 Boston Biomedical, Inc. Recent Developments
11.15 Bristol-Myers Squibb Company
11.15.1 Bristol-Myers Squibb Company Company Information
11.15.2 Bristol-Myers Squibb Company Overview
11.15.3 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Products and Services
11.15.5 Bristol-Myers Squibb Company Recent Developments
11.16 Calithera Biosciences, Inc.
11.16.1 Calithera Biosciences, Inc. Company Information
11.16.2 Calithera Biosciences, Inc. Overview
11.16.3 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.16.5 Calithera Biosciences, Inc. Recent Developments
11.17 Celgene Corporation
11.17.1 Celgene Corporation Company Information
11.17.2 Celgene Corporation Overview
11.17.3 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Products and Services
11.17.5 Celgene Corporation Recent Developments
11.18 Cornerstone Pharmaceuticals, Inc.
11.18.1 Cornerstone Pharmaceuticals, Inc. Company Information
11.18.2 Cornerstone Pharmaceuticals, Inc. Overview
11.18.3 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.18.5 Cornerstone Pharmaceuticals, Inc. Recent Developments
11.19 CTI BioPharma Corp.
11.19.1 CTI BioPharma Corp. Company Information
11.19.2 CTI BioPharma Corp. Overview
11.19.3 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.19.4 CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Products and Services
11.19.5 CTI BioPharma Corp. Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Relapsed Acute Myeloid Leukemia Drug Value Chain Analysis
12.2 Relapsed Acute Myeloid Leukemia Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Relapsed Acute Myeloid Leukemia Drug Production Mode & Process
12.4 Relapsed Acute Myeloid Leukemia Drug Sales and Marketing
12.4.1 Relapsed Acute Myeloid Leukemia Drug Sales Channels
12.4.2 Relapsed Acute Myeloid Leukemia Drug Distributors
12.5 Relapsed Acute Myeloid Leukemia Drug Customers
13 Market Dynamics
13.1 Relapsed Acute Myeloid Leukemia Drug Industry Trends
13.2 Relapsed Acute Myeloid Leukemia Drug Market Drivers
13.3 Relapsed Acute Myeloid Leukemia Drug Market Challenges
13.4 Relapsed Acute Myeloid Leukemia Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of aNK Program
Table 3. Major Manufacturers of AT-9283
Table 4. Major Manufacturers of BI-836858
Table 5. Major Manufacturers of Binimetinib
Table 6. Major Manufacturers of BL-8040
Table 7. Major Manufacturers of Others
Table 8. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 9. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2018-2023) & (US$ Million)
Table 11. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2018-2023)
Table 12. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2024-2034) & (US$ Million)
Table 13. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region (2024-2034)
Table 14. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 15. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2018-2023) & (K Pcs)
Table 16. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2018-2023)
Table 17. Global Relapsed Acute Myeloid Leukemia Drug Sales by Region (2024-2034) & (K Pcs)
Table 18. Global Relapsed Acute Myeloid Leukemia Drug Sales Market Share by Region (2024-2034)
Table 19. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 20. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 21. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 22. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Manufacturers (2018-2023)
Table 23. Global Relapsed Acute Myeloid Leukemia Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 24. Global Key Players of Relapsed Acute Myeloid Leukemia Drug, Industry Ranking, 2021 VS 2024
Table 25. Global Relapsed Acute Myeloid Leukemia Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 26. Global Relapsed Acute Myeloid Leukemia Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Relapsed Acute Myeloid Leukemia Drug as of 2024)
Table 27. Global Key Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Manufacturing Base Distribution and Headquarters
Table 28. Global Key Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Product Offered and Application
Table 29. Global Key Manufacturers of Relapsed Acute Myeloid Leukemia Drug, Date of Enter into This Industry
Table 30. Mergers & Acquisitions, Expansion Plans
Table 31. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 32. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 33. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Type (2018-2023)
Table 34. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Type (2024-2034)
Table 35. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2023) & (US$ Million)
Table 36. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 37. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2018-2023)
Table 38. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Type (2024-2034)
Table 39. Relapsed Acute Myeloid Leukemia Drug Price by Type (2018-2023) & (USD/Pcs)
Table 40. Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 41. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 42. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 43. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Application (2018-2023)
Table 44. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Application (2024-2034)
Table 45. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2023) & (US$ Million)
Table 46. Global Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 47. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2018-2023)
Table 48. Global Relapsed Acute Myeloid Leukemia Drug Revenue Share by Application (2024-2034)
Table 49. Relapsed Acute Myeloid Leukemia Drug Price by Application (2018-2023) & (USD/Pcs)
Table 50. Global Relapsed Acute Myeloid Leukemia Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 51. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023) & (US$ Million)
Table 52. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 53. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 54. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 55. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2023) & (US$ Million)
Table 56. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 57. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 58. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 59. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2023) & (US$ Million)
Table 60. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 61. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 62. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2018-2023) & (US$ Million)
Table 63. North America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2024-2034) & (US$ Million)
Table 64. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 65. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 66. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 67. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023) & (US$ Million)
Table 68. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 69. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 70. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2023) & (US$ Million)
Table 71. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 72. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 73. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 74. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2023) & (US$ Million)
Table 75. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 76. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 77. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2018-2023) & (US$ Million)
Table 78. Europe Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2024-2034) & (US$ Million)
Table 79. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 80. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 81. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 82. China Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023) & (US$ Million)
Table 83. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 84. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 85. China Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2023) & (US$ Million)
Table 86. China Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 87. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 88. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 89. China Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2023) & (US$ Million)
Table 90. China Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 91. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 92. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023) & (US$ Million)
Table 93. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 94. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 95. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2023) & (US$ Million)
Table 96. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 97. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 98. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 99. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2023) & (US$ Million)
Table 100. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 101. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 102. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2018-2023) & (US$ Million)
Table 103. APAC Relapsed Acute Myeloid Leukemia Drug Revenue by Region (2024-2034) & (US$ Million)
Table 104. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 105. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 107. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Company (2018-2023) & (US$ Million)
Table 108. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 109. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Type (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 113. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 114. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2018-2023) & (US$ Million)
Table 115. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Application (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 117. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2018-2023) & (US$ Million)
Table 118. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue by Country (2024-2034) & (US$ Million)
Table 119. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 120. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 121. 4SC AG Company Information
Table 122. 4SC AG Description and Overview
Table 123. 4SC AG Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 124. 4SC AG Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 125. 4SC AG Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 126. 4SC AG Recent Developments
Table 127. AbbVie Inc. Company Information
Table 128. AbbVie Inc. Description and Overview
Table 129. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 130. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 131. AbbVie Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 132. AbbVie Inc. Recent Developments
Table 133. Actinium Pharmaceuticals, Inc. Company Information
Table 134. Actinium Pharmaceuticals, Inc. Description and Overview
Table 135. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 136. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 137. Actinium Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 138. Actinium Pharmaceuticals, Inc. Recent Developments
Table 139. Agios Pharmaceuticals, Inc. Company Information
Table 140. Agios Pharmaceuticals, Inc. Description and Overview
Table 141. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 142. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 143. Agios Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 144. Agios Pharmaceuticals, Inc. Recent Developments
Table 145. Amgen Inc. Company Information
Table 146. Amgen Inc. Description and Overview
Table 147. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 148. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 149. Amgen Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 150. Amgen Inc. Recent Developments
Table 151. Arog Pharmaceuticals, Inc. Company Information
Table 152. Arog Pharmaceuticals, Inc. Description and Overview
Table 153. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 154. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 155. Arog Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 156. Arog Pharmaceuticals, Inc. Recent Developments
Table 157. Array BioPharma Inc. Company Information
Table 158. Array BioPharma Inc. Description and Overview
Table 159. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 160. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 161. Array BioPharma Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 162. Array BioPharma Inc. Recent Developments
Table 163. Astellas Pharma Inc. Company Information
Table 164. Astellas Pharma Inc. Description and Overview
Table 165. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 166. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 167. Astellas Pharma Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 168. Astellas Pharma Inc. Recent Developments
Table 169. Astex Pharmaceuticals, Inc. Company Information
Table 170. Astex Pharmaceuticals, Inc. Description and Overview
Table 171. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 172. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 173. Astex Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 174. Astex Pharmaceuticals, Inc. Recent Developments
Table 175. AstraZeneca Plc Company Information
Table 176. AstraZeneca Plc Description and Overview
Table 177. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 178. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 179. AstraZeneca Plc Relapsed Acute Myeloid Leukemia Drug SWOT Analysis
Table 180. AstraZeneca Plc Recent Developments
Table 181. AVEO Pharmaceuticals, Inc. Company Information
Table 182. AVEO Pharmaceuticals, Inc. Description and Overview
Table 183. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 184. AVEO Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 185. AVEO Pharmaceuticals, Inc. Recent Developments
Table 186. BioLineRx, Ltd. Company Information
Table 187. BioLineRx, Ltd. Description and Overview
Table 188. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 189. BioLineRx, Ltd. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 190. BioLineRx, Ltd. Recent Developments
Table 191. Boehringer Ingelheim GmbH Company Information
Table 192. Boehringer Ingelheim GmbH Description and Overview
Table 193. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 194. Boehringer Ingelheim GmbH Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 195. Boehringer Ingelheim GmbH Recent Developments
Table 196. Boston Biomedical, Inc. Company Information
Table 197. Boston Biomedical, Inc. Description and Overview
Table 198. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 199. Boston Biomedical, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 200. Boston Biomedical, Inc. Recent Developments
Table 201. Bristol-Myers Squibb Company Company Information
Table 202. Bristol-Myers Squibb Company Description and Overview
Table 203. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 204. Bristol-Myers Squibb Company Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 205. Bristol-Myers Squibb Company Recent Developments
Table 206. Calithera Biosciences, Inc. Company Information
Table 207. Calithera Biosciences, Inc. Description and Overview
Table 208. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 209. Calithera Biosciences, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 210. Calithera Biosciences, Inc. Recent Developments
Table 211. Celgene Corporation Company Information
Table 212. Celgene Corporation Description and Overview
Table 213. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 214. Celgene Corporation Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 215. Celgene Corporation Recent Developments
Table 216. Cornerstone Pharmaceuticals, Inc. Company Information
Table 217. Cornerstone Pharmaceuticals, Inc. Description and Overview
Table 218. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 219. Cornerstone Pharmaceuticals, Inc. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 220. Cornerstone Pharmaceuticals, Inc. Recent Developments
Table 221. CTI BioPharma Corp. Company Information
Table 222. CTI BioPharma Corp. Description and Overview
Table 223. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 224. CTI BioPharma Corp. Relapsed Acute Myeloid Leukemia Drug Product and Services
Table 225. CTI BioPharma Corp. Recent Developments
Table 226. Key Raw Materials Lists
Table 227. Raw Materials Key Suppliers Lists
Table 228. Relapsed Acute Myeloid Leukemia Drug Distributors List
Table 229. Relapsed Acute Myeloid Leukemia Drug Customers List
Table 230. Relapsed Acute Myeloid Leukemia Drug Market Trends
Table 231. Relapsed Acute Myeloid Leukemia Drug Market Drivers
Table 232. Relapsed Acute Myeloid Leukemia Drug Market Challenges
Table 233. Relapsed Acute Myeloid Leukemia Drug Market Restraints
Table 234. Research Programs/Design for This Report
Table 235. Key Data Information from Secondary Sources
Table 236. Key Data Information from Primary Sources
List of Figures
Figure 1. Relapsed Acute Myeloid Leukemia Drug Product Picture
Figure 2. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Type in 2024 & 2034
Figure 4. aNK Program Product Picture
Figure 5. AT-9283 Product Picture
Figure 6. BI-836858 Product Picture
Figure 7. Binimetinib Product Picture
Figure 8. BL-8040 Product Picture
Figure 9. Others Product Picture
Figure 10. Global Relapsed Acute Myeloid Leukemia Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 11. Global Relapsed Acute Myeloid Leukemia Drug Market Share by Application in 2024 & 2034
Figure 12. Clinic
Figure 13. Hospital
Figure 14. Others
Figure 15. Relapsed Acute Myeloid Leukemia Drug Report Years Considered
Figure 16. Global Relapsed Acute Myeloid Leukemia Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 17. Global Relapsed Acute Myeloid Leukemia Drug Revenue 2018-2034 (US$ Million)
Figure 18. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 19. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity 2018-2034 (K Pcs)
Figure 20. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Region (2018-2023)
Figure 21. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. North America Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. Europe Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. China Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. APAC Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 31. Middle East, Africa and Latin America Relapsed Acute Myeloid Leukemia Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Relapsed Acute Myeloid Leukemia Drug Sales Quantity in 2024
Figure 33. The Top 10 and Top 5 Players Market Share by Relapsed Acute Myeloid Leukemia Drug Revenue in 2024
Figure 34. Relapsed Acute Myeloid Leukemia Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 35. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2018-2034)
Figure 37. Global Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2018-2034)
Figure 39. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company in 2024
Figure 40. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Company in 2024
Figure 41. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2018-2034)
Figure 43. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2018-2034)
Figure 45. North America Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2018-2034)
Figure 46. North America Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Country (2018-2034)
Figure 47. U.S. Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Company in 2024
Figure 50. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company in 2024
Figure 51. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2018-2034)
Figure 53. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2018-2034)
Figure 55. Europe Relapsed Acute Myeloid Leukemia Drug Revenue Share by Country (2018-2034)
Figure 56. Europe Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 58. France Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 62. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Company in 2024
Figure 63. China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company in 2024
Figure 64. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2018-2034)
Figure 66. China Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2018-2034)
Figure 68. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Company in 2024
Figure 69. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Company in 2024
Figure 70. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Type (2018-2034)
Figure 72. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Market Share by Application (2018-2034)
Figure 74. APAC Relapsed Acute Myeloid Leukemia Drug Revenue Share by Region (2018-2034)
Figure 75. APAC Relapsed Acute Myeloid Leukemia Drug Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Relapsed Acute Myeloid Leukemia Drug Revenue (2018-2034) & (US$ Million)
Figure 77. South